Found 52 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTIN-METHYL-D-ASPARTIC ACID RECEPTOR (NMDAR) OR ANTILEUCINE-RICH GLIOMA-INACTIVATED 1 (LGI1) ENCEPHALITIS
This is a phase 1, randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy study of oral verdiperstat (BHV-3241) in patients with semantic variant Primary Progressive Aphasia (svPPA) due to Frontotemporal Lobar Degeneration with TDP-43 pathology (FTLD-TDP).
This is a double-blind, randomized, multicenter international Phase 3 study of CAEL-101 combined with standard of care plasma cell dyscrasia (PCD) treatment versus placebo combined with standard of care PCD treatment in Mayo stage IIIa PCD treatment-naïve AL amyloidosis patients. T
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a new pacemaker program called atrioventricular interval modulation (AVIM). The sponsor aims to enroll about 500 participants from up to 100 centers worldwide into this study. Participation lasts up to 37 months.
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline. We would like to rely on WCG as the IRB of record for this study.
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and/or predicted to receive a large volume blood product
This is a prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel AV interval modulation (AVIM) algorithm downloaded into a previously implanted dual-chamber Medtronic pacemaker. Patients within 90 days of de novo implant of an Astra/Azure pacemaker also having uncontrolled hypertension may be approached for …
Requesting a reliance agreement with an external IRB. The purpose of this double-blind, placebo-controlled trial is to evaluate the safety and efficacy of treatment with plozasiran on the reduction of fasting serum TG from Baseline in subjects with severe hypertriglyceridemia who have fasting TG levels above 500 mg/dL (5.65 mmol/L).
